NO329940B1 - Anvendelse av crospovidon med natriumhydroksyd for a stabilisere rabeprazol - Google Patents
Anvendelse av crospovidon med natriumhydroksyd for a stabilisere rabeprazol Download PDFInfo
- Publication number
- NO329940B1 NO329940B1 NO20021875A NO20021875A NO329940B1 NO 329940 B1 NO329940 B1 NO 329940B1 NO 20021875 A NO20021875 A NO 20021875A NO 20021875 A NO20021875 A NO 20021875A NO 329940 B1 NO329940 B1 NO 329940B1
- Authority
- NO
- Norway
- Prior art keywords
- crospovidone
- benzimidazole
- rabeprazole
- sodium hydroxide
- based compound
- Prior art date
Links
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 title claims abstract description 66
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960000913 crospovidone Drugs 0.000 title claims abstract description 45
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 title claims abstract description 45
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 title claims abstract description 45
- 229960004157 rabeprazole Drugs 0.000 title claims description 15
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000002702 enteric coating Substances 0.000 claims description 13
- 238000009505 enteric coating Methods 0.000 claims description 13
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 abstract description 36
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract description 32
- 238000009472 formulation Methods 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 7
- 230000000087 stabilizing effect Effects 0.000 abstract description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 11
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 10
- 229960001778 rabeprazole sodium Drugs 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- -1 rabeprazole Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29806399 | 1999-10-20 | ||
| PCT/JP2000/007285 WO2001028559A1 (fr) | 1999-10-20 | 2000-10-19 | Procede de stabilisation de composes benzimidazoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021875D0 NO20021875D0 (no) | 2002-04-19 |
| NO20021875L NO20021875L (no) | 2002-06-04 |
| NO329940B1 true NO329940B1 (no) | 2011-01-24 |
Family
ID=17854666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021875A NO329940B1 (no) | 1999-10-20 | 2002-04-19 | Anvendelse av crospovidon med natriumhydroksyd for a stabilisere rabeprazol |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7220762B1 (fr) |
| EP (1) | EP1222922B1 (fr) |
| JP (1) | JP4081273B2 (fr) |
| KR (1) | KR20020038759A (fr) |
| CN (1) | CN1197574C (fr) |
| AT (1) | ATE369857T1 (fr) |
| AU (1) | AU782538B2 (fr) |
| CA (1) | CA2387746C (fr) |
| CY (1) | CY1107506T1 (fr) |
| DE (1) | DE60036014T2 (fr) |
| DK (1) | DK1222922T3 (fr) |
| ES (1) | ES2288876T3 (fr) |
| HU (1) | HU229213B1 (fr) |
| MX (1) | MXPA02003762A (fr) |
| NO (1) | NO329940B1 (fr) |
| PT (1) | PT1222922E (fr) |
| RU (1) | RU2259828C2 (fr) |
| TW (1) | TWI268779B (fr) |
| WO (1) | WO2001028559A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE526022T1 (de) * | 1998-04-20 | 2011-10-15 | Eisai R&D Man Co Ltd | Stabilisierte zusammenstellungen die benzimidazole enthalten |
| AR036354A1 (es) * | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
| US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
| CN1589156A (zh) * | 2001-11-21 | 2005-03-02 | 卫材株式会社 | 含有对酸不稳定的生理活性化合物的制剂组合物及其制法 |
| RU2334286C2 (ru) | 2002-06-28 | 2008-09-20 | Эл Джи Электроникс Инк. | Носитель записи со структурой данных для управления записью и воспроизведением записанных на нем данных нескольких каналов и способы и устройства записи и воспроизведения |
| US7720356B2 (en) | 2002-11-12 | 2010-05-18 | Lg Electronics Inc | Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses |
| US7664372B2 (en) | 2002-11-20 | 2010-02-16 | Lg Electronics Inc. | Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses |
| TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| JPWO2005092336A1 (ja) * | 2004-03-26 | 2008-02-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 溶出制御製剤とその製造方法 |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| EP1930030A1 (fr) * | 2005-09-29 | 2008-06-11 | Eisai R&D Management Co., Ltd. | Préparation pour impulsion ayant de meilleures propriétés de désintégration in vivo |
| WO2008062320A2 (fr) * | 2006-10-06 | 2008-05-29 | Eisai R&D Management Co., Ltd | Formulations à libération prolongée d'un inhibiteur de la pompe à protons |
| CN100411613C (zh) * | 2006-12-08 | 2008-08-20 | 中国药科大学 | 一种奥美拉唑速释固体制剂及其制备方法 |
| WO2008129517A2 (fr) * | 2007-04-23 | 2008-10-30 | Ranbaxy Laboratories Limited | Composition pharmaceutique à libération prolongée stabilisée de rabéprazole |
| JP5399749B2 (ja) * | 2008-03-27 | 2014-01-29 | 沢井製薬株式会社 | プロトンポンプ阻害剤を含有する被覆微粒子 |
| WO2010117756A2 (fr) * | 2009-03-31 | 2010-10-14 | Dr. Reddy's Laboratories Ltd | Formulations pharmaceutiques de benzimidazole substitué |
| US20150209432A1 (en) | 2012-07-26 | 2015-07-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
| RU2554735C1 (ru) * | 2014-08-20 | 2015-06-27 | Открытое Акционерное Общество "Татхимфармпрепараты" | Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения |
| KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB189698A (en) | 1921-12-29 | 1922-12-07 | Miniere & Ind Franco Bresilien | Method for the treatment of monazite and other phosphate ores |
| US4471638A (en) * | 1982-03-26 | 1984-09-18 | Steelcase Inc. | Front removable lock |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| CA1327010C (fr) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production |
| ZA871177B (en) | 1986-02-21 | 1988-10-26 | Nihon Nohyaku Co Ltd | 1,3-diketone derivatives and their use |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| AU619444B2 (en) | 1986-06-02 | 1992-01-30 | Nippon Chemiphar Co. Ltd. | 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| JPH0656665A (ja) | 1992-08-03 | 1994-03-01 | Nippon Chemiphar Co Ltd | イミダゾール誘導体を含有する胃溶性抗潰瘍剤 |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302395D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| DE29522419U1 (de) | 1994-07-08 | 2003-07-03 | AstraZeneca AB, Södertälje | Tablettierte Mehrfacheinheits-Dosisform |
| ES2094694B1 (es) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| US5708017A (en) | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| ATE262332T1 (de) * | 1995-09-21 | 2004-04-15 | Pharma Pass Ii Llc | Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren |
| BE1009764A3 (nl) | 1995-11-06 | 1997-08-05 | Dsm Nv | Werkwijze voor de bereiding van een alpha-alkylkaneelaldehyde. |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| JPH09216817A (ja) | 1996-02-08 | 1997-08-19 | Amano Pharmaceut Co Ltd | 防湿性且つ易水崩壊性コーティング製剤 |
| DE69713948D1 (de) | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
| AU3191397A (en) | 1996-06-25 | 1998-01-14 | Takeda Chemical Industries Ltd. | Oxazolone derivatives and their use as anti-(helicobacter pylori) agent |
| GB9710800D0 (en) | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
| TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
| SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
| US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
| US20050244497A1 (en) | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
| ATE526022T1 (de) | 1998-04-20 | 2011-10-15 | Eisai R&D Man Co Ltd | Stabilisierte zusammenstellungen die benzimidazole enthalten |
| ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20040028737A1 (en) | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
-
2000
- 2000-10-19 RU RU2002113104/04A patent/RU2259828C2/ru not_active IP Right Cessation
- 2000-10-19 AU AU79502/00A patent/AU782538B2/en not_active Ceased
- 2000-10-19 WO PCT/JP2000/007285 patent/WO2001028559A1/fr active IP Right Grant
- 2000-10-19 MX MXPA02003762A patent/MXPA02003762A/es active IP Right Grant
- 2000-10-19 AT AT00969905T patent/ATE369857T1/de active
- 2000-10-19 US US10/110,679 patent/US7220762B1/en not_active Expired - Lifetime
- 2000-10-19 CN CNB008145970A patent/CN1197574C/zh not_active Expired - Fee Related
- 2000-10-19 ES ES00969905T patent/ES2288876T3/es not_active Expired - Lifetime
- 2000-10-19 EP EP00969905A patent/EP1222922B1/fr not_active Expired - Lifetime
- 2000-10-19 PT PT00969905T patent/PT1222922E/pt unknown
- 2000-10-19 DE DE60036014T patent/DE60036014T2/de not_active Expired - Lifetime
- 2000-10-19 KR KR1020027003596A patent/KR20020038759A/ko active Search and Examination
- 2000-10-19 CA CA2387746A patent/CA2387746C/fr not_active Expired - Fee Related
- 2000-10-19 DK DK00969905T patent/DK1222922T3/da active
- 2000-10-19 TW TW089121923A patent/TWI268779B/zh not_active IP Right Cessation
- 2000-10-19 HU HU0203333A patent/HU229213B1/hu not_active IP Right Cessation
- 2000-10-19 JP JP2001531389A patent/JP4081273B2/ja not_active Expired - Fee Related
-
2002
- 2002-04-19 NO NO20021875A patent/NO329940B1/no not_active IP Right Cessation
-
2007
- 2007-10-24 CY CY20071101368T patent/CY1107506T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60036014D1 (de) | 2007-09-27 |
| EP1222922B1 (fr) | 2007-08-15 |
| WO2001028559A1 (fr) | 2001-04-26 |
| CN1382049A (zh) | 2002-11-27 |
| AU782538B2 (en) | 2005-08-04 |
| PT1222922E (pt) | 2007-09-12 |
| HU229213B1 (en) | 2013-09-30 |
| US7220762B1 (en) | 2007-05-22 |
| TWI268779B (en) | 2006-12-21 |
| CA2387746C (fr) | 2010-06-29 |
| NO20021875D0 (no) | 2002-04-19 |
| DE60036014T2 (de) | 2008-04-30 |
| KR20020038759A (ko) | 2002-05-23 |
| CA2387746A1 (fr) | 2001-04-26 |
| AU7950200A (en) | 2001-04-30 |
| HUP0203333A2 (hu) | 2003-02-28 |
| HUP0203333A3 (en) | 2004-01-28 |
| JP4081273B2 (ja) | 2008-04-23 |
| NO20021875L (no) | 2002-06-04 |
| EP1222922A4 (fr) | 2006-04-12 |
| EP1222922A1 (fr) | 2002-07-17 |
| ES2288876T3 (es) | 2008-02-01 |
| ATE369857T1 (de) | 2007-09-15 |
| DK1222922T3 (da) | 2007-12-03 |
| CN1197574C (zh) | 2005-04-20 |
| MXPA02003762A (es) | 2002-09-30 |
| RU2259828C2 (ru) | 2005-09-10 |
| CY1107506T1 (el) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329940B1 (no) | Anvendelse av crospovidon med natriumhydroksyd for a stabilisere rabeprazol | |
| EP2331074B1 (fr) | Granulés, leur procédé de préparation et produits pharmaceutiques les contenant | |
| US8877238B2 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
| KR100421347B1 (ko) | 약학 혼합 제제 | |
| FI96274B (fi) | Menetelmä valmistaa pimobendaanin oraalisia lääkeainemuotoja | |
| EP1008354A1 (fr) | Compositions medicinales immediatement desintegrables | |
| WO2005013964A1 (fr) | Preparation pharmaceutique contenant du nateglinide | |
| CA2651138C (fr) | Composition pharmaceutique | |
| WO2005079751A2 (fr) | Compositions pharmaceutiques orales de candesartan cilexetil | |
| WO2005084648A1 (fr) | Compositions pharmaceutiques comprenant du candesartan cilexetil | |
| CA2662265A1 (fr) | Compositions d'imatinib | |
| WO2008129517A2 (fr) | Composition pharmaceutique à libération prolongée stabilisée de rabéprazole | |
| MX2007011119A (es) | Composiciones farmaceuticas de amlodipino y benazepril. | |
| EP2814465B1 (fr) | Formule pharmaceutique à stabilité améliorée | |
| US20070298108A1 (en) | Pharmaceutical Formulation | |
| JP2021517159A (ja) | ダビガトランエテキシレートを含む医薬組成物およびその調製方法 | |
| EP1895990A2 (fr) | Formulations contenant de l acide libre de pantoprazole et les sels de ce dernier | |
| WO2004075881A1 (fr) | Compositions pharmaceutiques stables de rabeprazole et leurs procedes de fabrication | |
| EP4088715A1 (fr) | Formulation pharmaceutique de valsartan et sacubitril | |
| WO2022119543A1 (fr) | Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine | |
| KR100679166B1 (ko) | 안정성이 증진된 약제학적 조성물 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |